Novartis AG (NVS) Holds Entresto Edge As Earnings Strengthen

Positive late-stage trial results for a key Novartis AG drug lifted investor confidence, and stocks have been trading up by 5.85 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading NVS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Q2 adjusted sales rose to DKK 78.49B, up 7% at constant currencies, with adjusted operating profit climbing 11% to DKK 33.39B, showing solid operating momentum at Novartis AG.
The FDA granted orphan drug designation to Novartis’ iptacopan for atypical hemolytic uremic syndrome, reinforcing the rare-disease pipeline story and future pricing power.
A UK court upheld Novartis’ Entresto patent and supplementary protection certificate, preserving market exclusivity there until at least 2028 for a drug that represents roughly 10% of sales.
The UK High Court ruled Accord Healthcare’s planned Entresto generic would infringe Novartis’ protection, keeping generic competition sidelined in the UK until 2028, subject to appeal.
Despite these wins, NVS slipped about 0.2–0.3% on the Entresto news as the broader healthcare sector traded soft, suggesting the legal victory was partly priced in.

Live Update At 12:32:30 EDT: On Tuesday, September 01, 2026 Novartis AG stock [NYSE: NVS] is trending up by 5.85%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

NVS has been grinding higher on the chart, backed by real numbers instead of hype. Recent Q2 results showed adjusted sales of DKK 78.49B, up 7% at constant currencies, while adjusted operating profit grew 11% to DKK 33.39B. That tells traders one thing: Novartis AG is growing the top line and expanding margins at the same time. That’s the kind of combo that usually supports a steady uptrend.

You can see it in the daily action. Over the past couple of weeks, NVS has pushed from the high‑$140s to around $160.96, a strong multi‑day move that signals persistent dip‑buying. Intraday, the 5‑minute tape around $160–$162 shows tight trading ranges and repeated support near $161, a sign of orderly accumulation rather than wild speculation.

More Breaking News

Fundamentals back this up. With trailing revenue around $56.67B and a price‑to‑sales near 5.18, the market is willing to pay up for Novartis AG’s earnings quality and pipeline. A roughly 33.3% pre‑tax margin and double‑digit returns on equity and capital signal an efficient, cash‑generating machine. For active traders, that often translates into a name that trends cleanly and respects technical levels.

Why Traders Are Watching NVS Now

NVS is on a lot of screens right now because the story lines up: strong earnings, legal wins, and pipeline progress all hitting within weeks. When Novartis AG printed Q2 constant‑currency sales growth of 7% and an 11% jump in adjusted operating profit, it confirmed that this is not just a defensive pharma plodder. Management is squeezing more profit out of every DKK of revenue, and that tends to support premium multiples.

The real kicker for traders is Entresto. Multiple UK court rulings backed Novartis AG against Accord Healthcare, upholding both the core Entresto patent and the supplementary protection certificate. The court said Accord’s planned generic would infringe, effectively locking in UK exclusivity for Entresto until 2028, subject to appeal. Since Entresto makes up roughly 10% of Novartis’ total sales, that is not a side note — it’s a pillar of the NVS cash‑flow story.

Here’s the twist: even with that legal win, NVS shares were modestly down 0.2–0.3% on the day in a soft healthcare tape. That tells traders the market either anticipated a favorable outcome or simply didn’t care in the short term. For those who trade fundamentals‑backed momentum, that kind of muted reaction to clearly positive news can set up medium‑term swing opportunities if the chart confirms.

Add in the FDA’s orphan drug designation for iptacopan in atypical hemolytic uremic syndrome, and the long game for Novartis AG gets stronger. Orphan status typically means better pricing and exclusivity if the drug gets approved. It won’t move near‑term revenue, but it adds another potential leg to the NVS growth story that longer‑term swing traders will be tracking.

Conclusion

For active traders, NVS is a textbook example of a large‑cap name where the narrative and the numbers actually match. Novartis AG is growing sales, expanding operating profit, and defending a key cash cow in Entresto through 2028 in the UK. At the same time, it is quietly building future optionality with assets like iptacopan winning FDA orphan designation in a rare, severe disease.

The chart backs the story. NVS has been trending from the mid‑$140s to around $161, with tight intraday action and support zones holding on normal pullbacks. That is the kind of behavior momentum traders like to see when they’re stalking multi‑day or multi‑week moves in a liquid, mega‑cap name. Valuation is not dirt cheap, but with strong margins, solid returns on capital, and a 3%‑plus dividend yield, the market is clearly rewarding execution at Novartis AG.

For traders in the Tim Sykes community, the playbook is the same as always: let price confirm the story, watch key support and resistance levels, and don’t fall in love with any ticker — even one as steady as NVS. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.” That kind of disciplined review process is what helps traders refine their setups and stay adaptable in changing markets. As Tim Sykes likes to say, “Patterns repeat, but the market doesn’t owe you anything — show up prepared, or don’t show up at all.” This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!